Oxybral

Quick links to important sections

Oxybral

Selected form

Method of action: Peripheral Vasodilators

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxybral

Quick Facts

Property Description
Active ingredient Vincamine (Indole Alkaloid)
Form Capsules, Tablets (including sustained-release forms), Solution for injection
Pharmacological class Cerebral Vasodilator, Nootropic
General purpose Supports cognitive function related to blood flow
Origin Naturally occurring alkaloid from the Vinca minor plant

Identity and Composition

Oxybral is a pharmaceutical preparation containing the active ingredient Vincamine, which is classified primarily as a cerebral vasodilator and a nootropic agent. Vincamine is a naturally occurring indole alkaloid derived from the Vinca minor plant, also known as the lesser periwinkle. The Vincamine molecule, defined by the empirical formula C21H26N2O3, is structurally recognized as an agent that affects the nervous and circulatory systems, positioning it specifically within the pharmacological category for circulatory support. Pharmacological studies have consistently supported Vincamine's core property as a cerebral flow enhancer, differentiating it from general peripheral vasodilators.

Oxybral is typically available as a single-ingredient product, offered in various pharmaceutical preparations to suit different needs. These forms include capsules, standard tablets, specialized sustained-release forms (like Oxybral SR), and a sterile solution for parenteral (injection) administration, allowing for flexible clinical use.


Classification and General Purpose

The medication's fundamental classification as a cerebral vasodilator dictates its primary action: it is intended to enhance regional cerebral blood flow, thereby optimizing the supply of oxygen and essential nutrients to brain tissue. The profile of Vincamine is characterized by its function in optimizing cerebral metabolism and flow. By promoting better circulation and metabolic activity, Oxybral's general purpose is to support overall cognitive function related to blood flow, such as improving the clarity or acuity of thought processes in situations where circulation is compromised.

What side effects are possible with Oxybral?

Possible Side Effects and Safety Information

The safety profile of Oxybral (vincamine) is structured by defining both potential systemic adverse reactions and critical constraints on use, as documented in official regulatory sources. The most crucial safety considerations are the contraindications, which are absolute prohibitions on using the medicine under certain conditions.

Documented Adverse Reactions

The documented adverse effects are classified by the System-Organ Class affected, though precise frequency classifications may vary regionally. Effects generally noted as common or expected include Gastrointestinal Disorders (such as nausea, vomiting, or diarrhea) and Nervous System Disorders (such as headaches, dizziness, or sleep disturbances).

Serious Adverse Reactions officially noted include rare events like severe allergic reactions (hypersensitivity) and the potential for cardiac disturbances.

Safety Constraints and Contraindications

The medicine is strictly contraindicated (must not be used) in patients with specific severe pre-existing conditions. These include:

  • Known hypersensitivity to the active substance or components.
  • Severe ischaemic heart disease or documented cardiac arrhythmia.
  • Acute phases of intracerebral hemorrhage or other bleeding in the central nervous system.

Regulatory agencies also advise against use in pregnancy and during lactation due to insufficient safety data. Caution is required when using this medicine concurrently with anticoagulants or other antiplatelet agents due to a potential increase in bleeding risk. The official safety profile emphasizes that these prohibitions establish the primary safety boundaries for the use of Vincamine.

Overdose and Emergency Response

Overdose Manifestations and Complications

The regulatory documentation for Oxybral (Vincamine), as established by government health authorities, provides specific mandates for emergency response but notes a lack of detailed clinical data regarding acute overdose.

The official prescribing information for Vincamine-containing products frequently indicates that no specific constellation of symptoms, signs, or physiological changes are formally documented within the designated overdose section. This regulatory position means that expected clinical presentations in cases of overexposure have not been officially described.

Similarly, the official labeling does not specify particular life-threatening outcomes or severe adverse events expected from an acute overdose of Vincamine. The regulatory documents also confirm that no specific antidote is known or available to reverse the potential effects of an overdose.

When to Seek Immediate Medical Help

Despite the absence of specific documented symptoms, any suspected or confirmed acute intoxication (Surdosage) with Oxybral necessitates that immediate medical attention must be sought. This action represents a mandatory regulatory requirement for all drug intoxications.

Management for a suspected overdose is officially described as symptomatic and supportive treatment, a general procedural step used when specific reversal agents or documented protocols are unavailable. This treatment will be administered and tailored by medical staff based strictly on the individual's clinical status and required monitoring.

Therapeutic Uses of Oxybral

Oxybral, containing the active substance vincamine, is relevant in contexts involving heightened systemic burden, applied across domains where additional symptomatic support is needed. This therapeutic use is generally relevant in conditions where symptoms may intensify temporarily. Vincamine-containing medicines are indicated for the adjuvant symptomatic treatment of chronic pathological cognitive and neurosensory deficits in the elderly.

Oxybral is commonly used to help with various symptoms related to age-related circulatory and neurological impairments. These symptoms can include issues with memory, concentration, and attention, as well as other conditions such as dizziness (vertigo) and ringing in the ears (tinnitus) that are associated with circulatory impairments. The therapeutic approach supports general well-being during symptomatic phases. It helps maintain a sense of stability when symptoms are more noticeable and contributes to easing the overall symptom load.

“It is considered relevant as a symptomatic treatment to address the effects of chronic deficit.”

Quick Fact: Relief for Neurosensory Symptoms

Symptom Category Therapeutic Benefit
Cognitive Deficits May assist with maintaining clarity of thought and focus
Dizziness / Tinnitus Assists with maintaining functional stability
Circulatory Deficits Provides supportive relief for the overall symptom load

Regulatory References

  1. ANSM - Résumé des Caractéristiques du Produit

Eligibility and Restrictions for Use

Who Can and Cannot Use Oxybral?

Eligibility to use Oxybral (Vincamine) is determined by official government regulatory standards that specify the approved patient population and conditions under which the medication is prohibited or restricted.

Eligibility and Exclusionary Criteria

Classification Population/Condition Regulatory Status
Approved Use Elderly patients Indicated for symptomatic treatment of chronic neurosensory deficits.
Absolute Contraindication Hypersensitivity to Vincamine or excipients Use is formally prohibited.
Conditional Use History of severe cardiovascular disease Requires caution and medical supervision.
Conditional Use Liver or kidney impairment Requires consultation for appropriate use.

Age and Reproductive Status Restrictions

Official labeling generally restricts use to the approved age group. Safety and efficacy for the pediatric population (children and adolescents) are not established, and use is not recommended.

Similarly, use is officially not recommended or advised to be avoided for women who are pregnant or breastfeeding due to a lack of sufficient safety data in these groups. All use must align strictly with the official prescribing information for the product.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Vincamine (Oxybral) is primarily characterized by a documented pharmacodynamic risk related to cardiac rhythm. This profile is structured by the established potential for Vincamine to contribute to the prolongation of the Q-Tc interval, a condition that affects the heart’s electrical system.

Interaction Scope and Restrictions

Medicinal products with documented interactions are those known to slow intracardiac conduction or cause QT interval prolongation. This includes specific medicinal product categories, such as certain antiarrhythmics, antibiotics, neuroleptics, and tricyclic antidepressants. The mechanistic basis for this interaction is an additive electrophysiologic effect on the cardiac tissue, resulting in an increased risk of developing severe ventricular rhythm disorders. The combination of Vincamine with any drug in this risk category is officially designated as inadvisable by regulatory bodies due to the potential for the life-threatening arrhythmia, Torsades de Pointes.

The regulatory documents do not contain explicit statements regarding clinically significant pharmacokinetic interactions, such as those mediated by CYP enzymes or drug transporters. Furthermore, there are no documented mandatory timing-based interaction rules requiring separation of administration, nor are there explicit restrictions regarding concomitant use with food, alcohol, or herbal products in the official prescribing information. The interaction profile is thus narrowly focused on this single pharmacodynamic constraint.

Mechanism of Action

The mechanism of action of Vincamine (Oxybral) involves the modulation of cerebral circulation and neuronal stabilization. These functions operate through distinct molecular pathways within the central nervous system.

Targeted Optimization of Cerebral Vascular Tone

The primary action involves the inhibition of Phosphodiesterase 1 (PDE1) within the smooth muscle of brain blood vessels. By blocking PDE1, Vincamine prevents the hydrolysis of key cellular messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). The subsequent elevation of these cyclic nucleotides triggers the relaxation of the vascular muscle. This cascade results in a selective increase in Regional Cerebral Blood Flow (rCBF), leading to enhanced delivery of oxygen and metabolic substrates to brain tissues.

Neuronal Membrane Stabilization and Metabolic Modulation

Vincamine also modulates neuronal function through a stabilizing effect. It acts as a blocker of voltage-dependent sodium channels, stabilizing neuronal membranes and limiting uncontrolled electrical activity. Additionally, it functions as an antioxidant, scavenging Free Radicals and mitigating cellular damage. These mechanisms collectively influence the brain's utilization of glucose and oxygen and modulate central neurotransmitter systems, contributing to the maintenance of cellular integrity and physiological function.

Dosage and Administration Information

How to use Oxybral: Official Administration Guidelines

The administration of Oxybral (Vincamine) is strictly defined by official regulatory instructions to standardize its use in clinical practice. The total daily dosage is always administered in a divided fashion over the course of the day.

Administration Scope

Feature Guideline
Route of administration Oral (Capsules/Tablets) and Intravenous (IV) (Solution for injection)
Dosing schedule (Adult) Total daily dose typically ranges from 40 to 80 mg of Vincamine base.
Timing in relation to meals Oral forms, such as coated tablets, must be administered during meals.
Age-group administration rules High-level regulatory summaries do not mandate specific dose adjustments for older adults or organ impairment.
Special procedural conditions Oral tablets/capsules must be swallowed whole and not crushed to maintain the intended release profile.

Instruction Classifications (High-Level)

Classification Description
Administration method type Oral and Parenteral (IV).
Frequency pattern Daily administration, with the total dose divided (e.g., two to three times per day).
Use-context constraints Intended for long-term management of chronic deficits.

Resulting Procedural Structure

The official instructions define a protocol centered on a quantified daily dose range and a requirement for routine intake. This structure ensures that the medicine is used in a controlled and precise manner over a chronic duration, emphasizing the importance of administering the correct form via the approved route (Oral or IV) and following the specific intake condition of swallowing the oral dosage unit whole and taking it during a meal.

Recent Clinical Evidence

Oxybral: Recent Clinical Evidence

Oxybral is a trade name for the substance vincamine, an indole alkaloid derived from the Vinca minor (lesser periwinkle) plant. Research and clinical use of vincamine have primarily focused on its potential role in addressing cerebrovascular insufficiency and associated cognitive deficits.


Research Focus and Findings

The research concerning vincamine is largely historical, focusing on its proposed mechanism as a vasodilator and neuroprotective agent. These studies have explored its potential influence on brain function by examining factors such as:

  • Cerebral Blood Flow (CBF): Studies suggest that vincamine may increase blood flow in the cerebral arteries, which could enhance oxygen and glucose delivery to brain tissue. This effect has been documented in both animal models and small human trials, although large-scale, methodologically rigorous studies are limited.
  • Cognitive Measures: Early, small placebo-controlled trials investigated vincamine in patients with mild to moderate dementia of vascular or degenerative (e.g., Alzheimer's) etiologies. In some instances, participants receiving vincamine showed reported improvements in cognitive performance assessments compared to the placebo group. However, systematic reviews often cite methodological limitations in these studies, concluding that the overall evidence remains insufficient to conclusively recommend its routine use.

Safety and Tolerability

Clinical data indicates that vincamine is generally well-tolerated at therapeutic doses used in clinical research. Reported adverse effects at higher doses in studies have included potential cardiac disturbances and hypotension, underscoring the need for careful administration and monitoring. Ongoing research continues to explore the full spectrum of its pharmacological activities and safety profile.

Key Studies & References

  1. Vincamine - Wikipedia (Used for basic chemical structure, uses in Europe vs. US, and general summary of clinical data)

Frequently Asked Questions (FAQ)

Common questions about Oxybral (FAQ)


Q: What are the most commonly reported side effects people mention when taking Oxybral?

Official product information indicates that common adverse effects are generally related to the gastrointestinal system, such as nausea or diarrhea, and the nervous system, which can include reports of headaches, dizziness, or sleep disturbances.


Q: Can Oxybral interact with supplements or vitamins?

Official prescribing information places a strong focus on interactions with prescription medicines that affect the heart's electrical activity or blood clotting. Official documentation does not contain explicit required restrictions regarding the concomitant use of general vitamins.


Q: Is Oxybral approved for use in children or teenagers?

According to official regulatory standards, the safety and effectiveness of this medicine have not been established for the pediatric population (children and adolescents). Therefore, its use in these age groups is not recommended.


Q: What should I do if I suspect an interaction between Oxybral and another medicine?

Official patient information advises patients to ensure their healthcare professional is informed of all medicines and products being taken before starting treatment. Regulatory guidance emphasizes that concerns regarding a potential interaction should be discussed with a healthcare professional.


Q: Are there any requirements regarding blood tests while taking Oxybral?

Official documents note that caution is required and medical supervision is necessary when the medicine is used by patients with certain pre-existing conditions, such as liver, kidney, or heart disease. This medical supervision is necessary to ensure appropriate monitoring procedures are followed.


Q: Is Oxybral the same type of medicine as other blood flow enhancers?

Official regulatory classification designates the active substance, Vincamine, as a cerebral vasodilator and a nootropic agent. This means its mechanism of action is focused specifically on affecting blood flow in the brain, differentiating it from general peripheral blood flow enhancers.


Q: How long does it usually take to notice any effects from Oxybral?

The medicine is intended for the long-term management of chronic deficits. Official documents indicate that the intended therapeutic effects are generally expected to develop over a duration of time.


Q: Is Oxybral known to cause any long-term health issues?

The safety information documents the known adverse effects and contraindications. Clinical data available in official documents reports that the medicine has been observed to be well-tolerated at therapeutic doses used in research.


Q: Does Oxybral affect blood pressure?

Official documents note that the medicine's vasodilatory action can be associated with cardiovascular effects. These effects include a potential for hypotension (low blood pressure) or cardiac disturbances.


Q: Is it common to feel a mild headache when first starting Oxybral?

The official documentation lists headache as an adverse effect related to the nervous system. It does not typically classify the severity of the headache or specify the exact timing of its onset.


Q: Is Oxybral a blood thinner?

While the medicine's primary classification is a cerebral vasodilator, official regulatory documents advise that caution is required when it is used concurrently with anticoagulants (blood thinners) or antiplatelet agents. This is due to a documented potential for an increased bleeding risk when combined.


Q: What is the difference between Oxybral and Ginkgo Biloba supplements?

Oxybral is classified by regulatory bodies as a pharmaceutical agent (a cerebral vasodilator and nootropic) intended for the management of chronic deficits. This distinguishes it from herbal products like Ginkgo Biloba, which have a different regulatory status.


Q: Do studies support the use of Oxybral for memory issues?

Research has focused on the medicine's potential influence on cognitive measures in patients with conditions like mild to moderate dementia. However, systematic reviews have noted methodological limitations in the studies examined.


Q: Can Oxybral make you feel tired or drowsy?

Documented adverse reactions listed in official documents include nervous system disorders such as dizziness and sleep disturbances, which may include feelings of tiredness or drowsiness.


Q: Are there different strengths or versions of Oxybral available?

The medicine is officially available in several pharmaceutical preparations, which include capsules, standard tablets, specialized sustained-release forms (designed for slow, continuous action), and a sterile solution for injection.


Q: Is it normal for some effects of Oxybral to take weeks or months to appear?

The medicine is officially designated for the long-term management of chronic deficits. This use context indicates that the intended therapeutic effects are generally expected to develop gradually over a duration of time.


Q: Is Oxybral considered a treatment for tinnitus (ringing in the ears)?

The medicine is officially indicated for the symptomatic treatment of chronic neurosensory deficits. This broad category may include conditions associated with impaired circulation, such as those that contribute to symptoms like tinnitus.


Q: Does the body become dependent on Oxybral over time?

Official regulatory documents do not list the potential for physical or psychological dependence as a documented risk.


Q: Is Oxybral used for balancing dizziness or vertigo?

The medicine is officially indicated for the symptomatic treatment of chronic neurosensory deficits. This medical category encompasses conditions affecting balance and inner ear circulation, which can be underlying causes of vertigo or chronic dizziness.


Q: Are there any warnings about driving or operating machinery while on Oxybral?

Official patient information contains warnings that the ability to drive or operate machinery may be impaired if the user experiences certain side effects. These include nervous system effects such as dizziness or sleep disturbances.


Q: What kind of patient populations are typically included in Oxybral studies?

Research and clinical studies have primarily included patient populations diagnosed with conditions like cerebrovascular insufficiency and chronic neurosensory deficits. Trials have also investigated its use in individuals with mild to moderate forms of dementia.


Q: Does taking Oxybral at night cause insomnia?

Sleep disturbances are listed as a documented adverse effect of the medicine. Based on clinical observation, adjusting the timing of administration to earlier in the day has been noted to potentially affect sleep-related issues.


Q: Are there specific symptoms that indicate Oxybral may not be suitable for someone?

Regulatory documents state that signs of a serious adverse reaction warrant seeking medical attention. These can include symptoms consistent with a severe allergic reaction or signs of cardiac disturbances.


Q: What if I forget to mention all my current supplements to the prescribing doctor?

Official regulatory documents require that patients disclose all current medicines, supplements, or products they are using to their healthcare professional before starting treatment. This disclosure is a requirement for the assessment of potential interaction risks.


Q: Are there different brand names for the same active ingredient as Oxybral?

Yes, the active substance, Vincamine, is marketed under various brand names globally. These different names include Angiopac, Devincan, Minorin, and others, depending on the country.

How should Oxybral be stored and disposed of?

The storage and disposal of Oxybral (Vincamine) must adhere strictly to the rules documented in official regulatory labeling to ensure product integrity and safety.

Required Storage and Protection

Requirement Official Statement
Temperature Store below 30 C (86 F).
Protection Keep protected from light and moisture; store in the original outer carton.
Child Safety Keep out of the sight and reach of children.

Handling and Disposal Rules

For the injection solution, the medicine must be used immediately after opening, and any unused portion must be discarded. Do not dispose of unused or expired Oxybral by throwing it into household waste or flushing it down wastewater. The product must be returned to a pharmacy or designated collection system for disposal according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oxybral found in:

A-Z Index: